Tamoxifen doesn’t alter endometrial cancer outcome

	Tweet

For breast cancer patients who later developed endometrial cancer, prior treatment with tamoxifen does not reduce the chances of survival, researchers report.

Women with breast cancer also have an increased risk for cancer of the endometrium, the lining of the uterus, Dr. Karen H. Lu and colleagues note in the July issue of Obstetrics and Gynecology. While tamoxifen is effective in preventing breast cancer and its recurrence, the drug’s effect on prognosis when endometrial cancer occurs has been unclear.

To investigate, Lu’s team, from M. D. Anderson Cancer Center in Houston, analyzed data on 89 women who developed endometrial cancer after surviving breast cancer. Forty-six of the patients had taken tamoxifen.

Clinically, endometrial cancer was similar in tamoxifen users and non-users, the investigators found. Moreover, there was no significant difference between the groups in mortality overall or specifically due to endometrial cancer.

However, the interval from breast cancer to endometrial cancer diagnosis averaged 77.2 months in tamoxifen users, whereas the interval in nonusers was 121.3 months, Lu and colleagues report.

SOURCE: Obstetrics and Gynecology, July 2004.

RELATED STORIES:
Japanese Women Show Lower Incidence of Breast Cancer Recurrence   Breast-feeding cuts genetic breast cancer risk   Underactive Thyroid Cuts Breast Cancer Risk   Breast exam adds little to mammography: study   U.S. panel rejects Inamed silicone breast implants   Kylie’s case shows breast cancer can strike early   Big Differences In Countries Masectomy Rates   Gene mutations tied to less invasive breast cancer   Students, staff helping teacher cope with breast cancer   Processed Soy Products Linked To Tumour Growth   Gene may sway fish oil’s breast cancer benefit   LA Yoga Study Seeking Breast Cancer Survivors

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]